Analyst Reco. AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 01:02:27 2024-12-10 pm EST			5-day change	1st Jan Change
175.59 ^USD	-0.56%		-3.30%	+13.25%

Dec. 09	AbbVie Reports Durable Results from Mono, Combo Therapy for Blood Cancer	MT
Dec. 09	Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Analyst recommendations: Applovin, Chewy, Netflix, Deliveroo, Diageo...	Dec. 05
Daiwa Securities Downgrades AbbVie to Neutral From Outperform, Adjusts Price Target to $180 From $210	Dec. 05	MT
Leerink Partners Upgrades AbbVie to Outperform From Market Perform, Price Target is $206	Nov. 22	MT
Wells Fargo Adjusts Price Target on AbbVie to $195 From $205, Maintains Overweight Rating	Nov. 18	MT
Redburn Atlantic Adjusts AbbVie's Price Target to $216 From $215, Keeps Buy Rating	Nov. 15	MT
Deutsche Bank Adjusts Price Target on AbbVie to $177 From $180, Keeps Hold Rating	Nov. 14	MT
JPMorgan Adjusts Price Target on AbbVie to $200 From $210, Keeps Overweight Rating	Nov. 13	MT
UBS Lowers Price Target on AbbVie to $181 From $200, Keeps Neutral Rating	Nov. 12	MT
Goldman Sachs Cuts AbbVie Price Target to $205 From $210, Maintains Buy Rating	Nov. 12	MT
Berenberg Adjusts Price Target on AbbVie to $165 From $170, Maintains Hold Rating	Nov. 12	MT
HSBC Adjusts Price Target on AbbVie to $220 From $230, Maintains Buy Rating	Nov. 12	MT
Morgan Stanley Adjusts Price Target on AbbVie to $224 From $231, Maintains Overweight Rating	Nov. 12	MT
BMO Capital Adjusts Price Target on AbbVie to $208 From $228, Maintains Outperform Rating	Nov. 12	MT
Raymond James Cuts AbbVie Price Target to $218 From $221	Nov. 11	MT
Citigroup Adjusts AbbVie Price Target to $215 From $226	Nov. 11	MT
HSBC Adjusts Price Target on AbbVie to $230 From $215, Maintains Buy Rating	Nov. 06	MT
Guggenheim Adjusts Price Target on AbbVie to $221 From $212, Maintains Buy Rating	Nov. 06	MT
Daiwa Securities Adjusts AbbVie Price Target to $210 From $190	Nov. 05	MT
Deutsche Bank Adjusts AbbVie Price Target to $180 From $175, Maintains Hold Rating	Nov. 05	MT
Argus Upgrades AbbVie to Buy From Hold, Price Target is $220	Nov. 04	MT
Goldman Sachs Raises Price Target on AbbVie to $210 From $208	Nov. 01	MT
UBS Adjusts Price Target on AbbVie to $200 From $195, Maintains Neutral Rating	Oct. 31	MT
Raymond James Adjusts Price Target on AbbVie to $221 From $200, Maintains Outperform Rating	Oct. 31	MT
BMO Capital Adjusts Price Target on AbbVie to $228 From $220, Maintains Outperform Rating	Oct. 31	MT
Piper Sandler Adjusts Price Target on AbbVie to $212 From $209, Maintains Overweight Rating	Oct. 31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Analyst Reco.

Filters